Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 19/20 | 0.55 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293010 | 1.00 | MALT1 (0.55) | MALT1BIRC3KDM4ENPC1LMNA | |
| SCHEMBL18787821 | 1.00 | MALT1 (0.55) | MALT1BIRC3KDM4ENPC1LMNA | |
| SCHEMBL25869771 | 0.89 | MALT1 (0.57) | MALT1BIRC3HTR7TMEM97SIGMAR1 | |
| SCHEMBL18787657 | 0.88 | MALT1 (0.52) | MALT1BIRC3KDM4ENPC1LMNA | |
| SCHEMBL17293051 | 0.88 | MALT1 (0.52) | MALT1BIRC3KDM4ENPC1LMNA | |
| SCHEMBL17293052 | 0.88 | MALT1 (0.52) | MALT1BIRC3KDM4ENPC1LMNA | |
| SCHEMBL18787664 | 0.87 | MALT1 (0.45) | MALT1BIRC3 | |
| SCHEMBL20913182 | 0.87 | MALT1 (0.45) | MALT1BIRC3 | |
| SCHEMBL18787663 | 0.87 | MALT1 (0.45) | MALT1BIRC3 | |
| SCHEMBL17292958 | 0.87 | MALT1 (0.47) | MALT1BIRC3KDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4466268-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023143249-A1 | PROTEIN DEGRADATION COMPOUND TARGETING MALT1 | 上海齐鲁制药研究中心有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023139479-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-07-27 | — | — | WO | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| US-10689366-B2 | Compounds for MALT1 degredation | CORNELL UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CORNELL UNIVERSITY (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3149001-B1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3149001-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | Novartis AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181747-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689366-B2 | Compounds for MALT1 degredation | CRBN, NFKB2, NFKB1 | MALT1 5/4885BIRC3 168/4885KDM4E 415/4885 |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MALT1 2/4885BIRC3 13/4885KDM4E 3265/4885 |
| US-20190263785-A1 | COMPOUNDS FOR MALT1 DEGRADATION | CRBN, NFKB2, NFKB1 | MALT1 7/4885BIRC3 111/4885KDM4E 555/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | MALT1 4/4885BIRC3 49/4885KDM4E 3024/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MALT1 2/4885BIRC3 13/4885KDM4E 3265/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | MALT1 3/4885BIRC3 40/4885KDM4E 3589/4885 |
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | MALT1, FKBP1B, FKBP1A | MALT1 1/4885BIRC3 99/4885KDM4E 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.